Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphoribosylamine–glycine ligase (GARS) is an enzyme that catalyzes the second step in purine biosynthesis, forming glycinamide ribonucleotide from ATP, 5-phospho-D-ribosylamine, and glycine. This enzymatic action is essential in the nucleotide biosynthesis pathway for both de novo synthesis of DNA and RNA precursors. In bacteria, GARS is a monofunctional enzyme encoded by the purD gene, while in higher eukaryotes, it can be part of multifuncional enzymes with other purine biosynthetic activities[1][2][3][4][5][10]. The human ortholog forms part of a trifunctional complex important for cellular growth and division. This enzyme is a potential antimicrobial drug target due to its essentiality in purine synthesis in microbes[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphoribosylamine–glycine ligase (GARS).